Nanolyze moves to AstraZeneca’s BioVentureHub

Nanolyze, a Swedish company developing bioanalytical technology to study nanoparticles, has moved into the BioVentureHub at the heart of the AstraZeneca Gothenburg R&D site.

Nanoparticles are sub-microscopic sized units that can be powerful vehicles for delivering drugs directly into cells. Nanolyze has developed a novel technology that can be used to analyze in real time, without fluorescence, how nanoparticles interact with proteins, molecules and microscopic organisms at single particle level.

Marianna Yanez Arteta, Associate Director in the Advanced Drug Delivery team at AstraZeneca, says, “We are constantly striving to accelerate how we can bring new drug modalities, such as oligonucleotides and mRNA, to patients safely and efficiently. Next generation drug‐delivery vehicles are dependent on bioanalytical tools capable of providing precise information about nanoparticles. It’s exciting to have Nanolyze join us in the BioVentureHub.”

Nils Löfgren, CEO at Nanolyze, says, “The BioVentureHub is the perfect environment for us to continue our growth journey. We’re excited about the opportunity to interact with and learn from AstraZeneca scientists and colleagues in the other BioVentureHub companies. We hope to get useful feedback on our product development process so we can continue to develop user-friendly, enabling solutions that can help pharma companies get medicines to patients faster.”

Magnus Björsne, CEO at AstraZeneca’s BioVentureHub, says, “We’re delighted that emerging life science companies, such as Nanolyze, want to join us and continue their growth journey together with us. The BioVentureHub continues to add more ingredients and flavours to the smorgasbord of collaborative and scientific innovation being catalyzed at the AstraZeneca Gothenburg site. We’re looking forward to helping Nils and his team interact, and explore value-generating opportunities, with colleagues at AstraZeneca and the other BioVentureHub companies.”

About Nanolyze
Nanolyze stems from research at Bio and Nanophysics at Chalmers and is currently delivering the first instruments to pilot users in Sweden and Germany. The initial research applications are within virus inhibition, extracellular vesicles, and lipid nanoparticles. The successful company growth has been nourished by being a part of the GU Ventures, which has also been housing the company until now. 

www.nanolyze.se